MLTX moonlaketx.com Net earnings per share for the last 12 months

Public company logo of MoonLake Immunotherapeutics (MLTX)

The primary risks for MoonLake Immunotherapeutics (MLTX) are centered on the final trial results for sonelokimab and competition with industry behemoths. The company's annual revenue per unit reflects current dynamics, with the value holding around -3.66, supplemented by strategic partnerships with global research centers. Proprietary anti-inflammatory developments create a long-term foundation for extracting high profits from chronic pathologies.

MLTX (MoonLake Corp) Net earnings per share (EPS TTM) history from 04/28/2023 to 11/17/2026

Analytical breakdowns and data insights for company MoonLake Corp (MLTX)

- stock price and consensus target price:
Fundamental company valuation:MoonLake Immunotherapeutics AG (MLTX)
Mass-produced product of MoonLake Pharma

This indicator measures the final return of a single security by allocating the company's total annual net income across all outstanding shares to assess real capital efficiency. By analyzing the rolling earnings per share (EPS) metric, an investor can see how the clinical research and manufacturing outsourcing strategy of MoonLake Immunotherapeutics (MLTX) impacts cost reduction and the bottom line.

Competitors of MoonLake Immunotherapeutics

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) CRNX|Earnings per share for the last twelve months NAMS (NewAmsterdam Pharma Company)|Earnings per share for the last twelve months soleno.life SLNO|Amicus Corp (FOLD) - Net earnings per one share for the last twelve months|ETNB - Earnings per share for the last twelve months|AGIO: Earnings per share for the last twelve months|GPCR: Net earnings per share (EPS TTM)|MDXG - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Rezolute Bio|Lexicon Corp (LXRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months mbxbio.com (MBX)|Net earnings per share (EPS TTM) altimmune.com (ALT)|Net earnings per share (EPS TTM) AARD (aardvarktherapeutics.com)|Net earnings per share for the last four quarters Sagimet Biosciences Inc. (SGMT)|BioAge Labs, Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Biomea Fusion Corp BMEA|QNCX: Net earnings per share (EPS TTM)|Fractyl Health, Inc. (GUTS) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months VTVT|Agape ATP Corporation - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) PLUR|SYBX - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) LPCN (lipocine.com)|Net earnings per share (EPS TTM) Matinas BioPharma MTNB|SPRB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Galecto Corp|CTCX (Carmell Corp) - Net earnings per share for the last 12 months|Lumos Pharma Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS